Study of fat and immune cells in melanoma
Part of Cancer, Skin clinical trials.
This trial looks at how fat and inflammatory cells affect melanoma by reviewing slides from past cases. It may help doctors better understand the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated for melanoma between 2006 and 2015, or treated at Christie Hospital between 2014 and 2019.
- Your tumor slides are available and of good quality.
- The full skin cross-section with the tumor must be visible on the slides.
- If you have a spitzoid melanoma, it must have unique features.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study analyzes blood and tissue samples from melanoma patients to identify biological markers that could help doctors better understand and treat the disease. Researchers will examine archived tissue samples and blood work to develop improved diagnostic tools.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.